IQVIA

Current directors and officers who also hold a role at another S&P 500 company.

• Ari BousbibHD · Director
• Carol BurtRMD · Director
• William G. Kaelin, Jr.LLY · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Apr 23, 2026

   On April 23, 2026, IQVIA Holdings Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the 2026 Incentive and Stock Award Plan (the “2026 Plan”). The material terms of the 2026 Plan are described in “Proposal No. 4 – Approval of IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 27, 2026. The 2026 Plan became effective immediately upon approval by the Company’s stockholders. The 2026 Plan replaces the IQVIA Holdings Inc. 2017 Incentive and Stock Award Plan (the “2017 Plan”) and assumes any shares remaining under the 2017 Plan as of the effective date of the 2026 Plan.

   Read the 8-K filing
2. Nov 5, 2025

   The Board of Directors (the “Board”) of IQVIA Holdings Inc. (the “Company”) appointed William G. Kaelin Jr., M.D. to the Board on November 5, 2025. The Board determined that Dr. Kaelin satisfies the New York Stock Exchange definition of “independent director.” In connection with his appointment to the Board, Dr. Kaelin is expected to enter into the Company’s standard indemnification agreement with non-management directors, a copy of which is filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on October 3, 2016 and is incorporated herein by reference. Dr. Kaelin will participate in the non-employee director compensation arrangements established by the Company for non-employee directors, as described under “Director Compensation” in the Company’s proxy statement dated February 28, 2025, for its 2025 annual meeting of stockholders.

   Read the 8-K filing
3. Sep 2, 2025

   Appointment of Michael J. Fedock as Executive Vice President and Chief Financial Officer, Effective February 28, 2026 On September 2, 2025, IQVIA Holdings Inc. (the “Company”) announced that Michael J. Fedock will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer (“CFO”), effective February 28, 2026. This transition is part of the Company’s previously announced Chief Financial Officer succession plan. Mr. Fedock, age 50, has more than 25 years of experience in the healthcare industry. He joined the Company in 2016, most recently serving as Senior Vice President, Financial Planning and Analysis since April 2021. From July 2019 to April 2021, Mr.

   Read the 8-K filing
4. May 10, 2024

   On May 6, 2024, IQVIA Holdings Inc. (the “Company”) announced that Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks, will transition from his current role effective May 15, 2024, and will become a senior advisor to the Chief Executive Officer (the “CEO”). In Mr. Knightly’s role as Senior Advisor to the CEO, he will receive compensation commensurate with this new role.

   Read the 8-K filing
5. Sep 26, 2023

   Appointment of Richard Staub III as President, Research & Development Solutions On September 25, 2023, IQVIA Holdings Inc. (the “Company”) announced the appointment of Richard Staub III to serve as President of its Research & Development Solutions (“R&DS”) business unit, effective September 25, 2023. Mr. Staub brings thirty-four years of relevant industry experience to this role. Mr. Staub previously served as the President of the R&DS business unit from 2016 to 2022. Mr. Staub then served as a senior advisor to the Company’s Chairman and CEO, where he worked closely with the R&DS business, having responsibility for key customer relationships, providing leadership on critical business issues and continuing to guide the overall strategic direction of the business.

   Read the 8-K filing
6. Oct 3, 2022

   IQVIA Holdings Inc. (the “Company”) announced today the resignation of Ronald A. Rittenmeyer, a member of the board of directors (the “Board”) and chairman of the Leadership Development and Compensation Committee (“LDCC”) of the Company, due to personal health reasons effective as of October 2, 2022. Mr. Rittenmeyer’s resignation was a personal decision and was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices .

   Read the 8-K filing
7. Jul 29, 2022

   Appointment of Keriann Cherofsky as Senior Vice President, Corporate Controller (Principal Accounting Officer) of the Company IQVIA Holdings Inc. (the “Company”) announced today the appointment of Keriann Cherofsky as Senior Vice President, Corporate Controller and principal accounting officer of the Company, effective August 1, 2022. Ms. Cherofsky, age 38, brings 16 years of relevant experience to her new role. From March 2019 to August 2022, she served as Assistant Controller of the Company. From November 2015 to March 2019, she led SEC reporting as Executive Director of JPMorgan Chase & Co. Prior to this, beginning in September 2006, she held various positions of increasing responsibility in PricewaterhouseCoopers LLP’s banking and capital markets assurance practice, most recently as Senior Manager. Under the terms of her offer, Ms.

   Read the 8-K filing
8. Mar 14, 2022

   On March 14, 2022, IQVIA Holdings Inc. (the “Company”) announced the appointment of Costa Panagos as President of its Research & Development Solutions (“R&DS”) business unit, effective April 1, 2022. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research organizations. Mr. Panagos joined the company in 1999 and has held numerous sales, operational and executive leadership positions across the Company. Mr. Panagos currently serves as President, Research & Development Operations, where he is responsible for the global delivery of all clinical trials, including traditional full-service trials, decentralized clinical trials and flexible staffing arrangements. Prior to his current role, Mr. Panagos served as chief executive officer of Q 2 Solutions, the Company’s global clinical trial laboratory business.

   Read the 8-K filing
9. Jan 27, 2022

   The Board of Directors (the “Board”) of IQVIA Holdings Inc. (the “Company”) appointed Leslie Wims Morris and Sheila A. Stamps to the Board on January 24, 2022 and January 26, 2022, respectively. Ms. Wims Morris will serve as a Class III director, and Ms. Stamps will serve as a Class I director. The Board determined that each of Ms. Wims Morris and Ms. Stamps satisfies the New York Stock Exchange definition of “independent director.” In connection with their respective appointments to the Board, Ms. Wims Morris and Ms. Stamps are both expected to enter into the Company’s standard indemnification agreement with non-management directors, a copy of which is filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on October 3, 2016 and is incorporated herein by reference. Each of Ms. Wims Morris and Ms.

   Read the 8-K filing
10. Jul 28, 2020

    In Mr. Bruehlman's new role as Executive Vice President and interim Chief Financial Officer, effective August 1, 2020, he will receive an annual base salary of $860,000, with an annual incentive target of 100% of his base salary, subject to the terms and conditions of the Company’s annual incentive program. In connection with his appointment, Mr. Bruehlman will also receive a restricted stock unit award on August 3, 2020, having an aggregate grant date fair value equal to $2,700,000, that vests ratably on each of the first three anniversaries following the grant date, subject to the terms and conditions of the Company’s 2017 Incentive and Stock Award Plan. Mr. Bruehlman will also participate in the Company’s standard benefit plans in the U.S. available to executives at his level in accordance with their terms.

    Read the 8-K filing
11. Jul 22, 2020

    Appointment of Ronald E. Bruehlman as Executive Vice President and interim Chief Financial Officer On July 21, 2020, IQVIA Holdings Inc. (the “Company”) announced the appointment of Ronald E. Bruehlman to serve as Executive Vice President and interim Chief Financial Officer, effective August 1, 2020. Mr. Bruehlman, age 59, previously served as Chief Financial Officer of IMS Health Holdings, Inc. (“IMS Health”) from 2011 until the merger of IMS Health and Quintiles Transnational Holdings Inc. in October 2016 (the “Merger”). Since the Merger, Mr. Bruehlman has served as a senior advisor to Ari Bousbib, Chairman and Chief Executive Officer of the Company. In addition, Mr. Bruehlman currently serves as Chairman of the Board of Directors at Q 2 Solutions, a joint venture between the Company and Quest Diagnostics Incorporated and a leading clinical trial laboratory services organization.

    Read the 8-K filing
12. Feb 21, 2019

    On February 21, 2019, the Board of Directors (the “Board”) of IQVIA Holdings Inc. (the “Company”) appointed Carol J. Burt to the Board, effective immediately. Ms. Burt will serve as a Class III director. The Board determined that Ms. Burt satisfies the New York Stock Exchange definition of “independent director.” In connection with her election to the Board, Ms. Burt entered into the Company’s standard indemnification agreement with non-management directors, a copy of which is filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on October 3, 2016 and is incorporated herein by reference. Ms. Burt will participate in the non-employee director compensation arrangements established by the Company for non-employee directors, as described under “Director Compensation” in the Company’s proxy statement dated March 1, 2018 for its 2018 annual meeting of stockholders.

    Read the 8-K filing
13. Sep 13, 2018

    Appointment of Emmanuel Korakis as Senior Vice President and Corporate Controller (Principal Accounting Officer) of the Company IQVIA Holdings Inc. (the “Company”) announced today the appointment of Emmanuel Korakis as Senior Vice President and Corporate Controller and principal accounting officer of the Company, effective November 1, 2018. Mr. Korakis, age 44, brings more than two decades of relevant experience to his new role. From July 2017 to September 2018, Mr. Korakis served as Corporate Controller and Chief Accounting Officer at American Express Global Business Travel.

    Read the 8-K filing
14. Jul 27, 2018

    Employment Agreement with Chairman and Chief Executive Officer On July 26, 2018, IQVIA Holdings Inc. (the “Company”) entered into a new employment agreement with its Chairman and Chief Executive Officer (the “CEO”). The agreement replaces the existing employment agreement between the CEO and the Company and continues until July 26, 2021, with automatic one-year renewals thereafter unless either party provides at least sixty days’ advance notice of non-renewal.

    Read the 8-K filing
15. Apr 12, 2018

    On May 3, 2016, in connection with the merger of Quintiles Transnational Holdings Inc. and IMS Health Holdings, Inc, we entered into a shareholders agreement (the “Shareholders Agreement”) with certain of the largest post-merger shareholders, including Dennis B. Gillings, CBE (“Dr. Gillings”) and certain of his affiliates. Pursuant to the Shareholders Agreement, Dr. Gillings was elected as our lead director through our 2018 annual meeting of stockholders, which was held on April 10, 2018 (the “Annual Meeting”). Following the Annual Meeting, Dr. Gillings retired from the board of directors. Dr. Gillings’ retirement, notice of which was provided to us on April 9, 2018, was not due to any disagreement with us on any matter relating to our operations, policies or practices.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.